ChemoCentryx, Inc.
CCXI · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.14 | 5.14 | -1.40 | 0.05 |
| FCF Yield | -3.96% | -2.37% | -3.15% | 2.87% |
| EV / EBITDA | -18.01 | -78.21 | -43.18 | -18.88 |
| Quality | ||||
| ROIC | -34.52% | -11.63% | -38.48% | -33.86% |
| Gross Margin | 99.06% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.57 | 1.47 | 1.26 | -0.43 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.58% | 14.81% | -24.18% | 55.35% |
| Free Cash Flow Growth | 1.98% | -36.16% | -554.63% | 275.40% |
| Safety | ||||
| Net Debt / EBITDA | 0.20 | 0.14 | 0.35 | -3.88 |
| Interest Coverage | 49.89 | -20.88 | -27.13 | -32.90 |
| Efficiency | ||||
| Inventory Turnover | 0.35 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -7,120.10 | 0.95 | 1.79 | 17.52 |